![]() |
Therapy Trends KOL Insight: Melanoma [2020]
Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab biosimilar combination threaten BMS' Opdivo/Yervoy domination of advanced melanoma treatment? And why do KOLs believe Iovance Biotherapeutics' pipeline lifileucel has the potential to change practice for patients' refractory to multiple-lines of therapy? US and European KOLs critically assess the prospects of launched and pipeline therapies.
Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness. |
|
Key questions answered
Examples of Therapies Covered
|
Partial List of Participating KOLs
|
![]() |
![]() |
![]() |
Continuous Monitoring Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts. |
Boardroom Ready Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders. |
Future Driven Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge. |
Deep Dive Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues. |
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved